As per ABS’s latest figures, Australia’s population increased by 1.4% for the year ended 31 December 2019. Some highlights include:
- Natural increase contributed 39.8% of annual population growth while remaining 60.8% was accounted by net overseas migration
- 305,800 births and 166,700 deaths registered in Australia in 2019
- 533,500 overseas migration arrivals and 322,900 departures in 2019 bringing net overseas migration to 210,700 people.
- Net overseas migration was down 16.5% compared to the previous year due to a rise in overseas migration departures by 14.4% paired with somewhat stable arrivals (fall of 0.2%)
Lauren Ford, ABS’s Demography Director stated that the population at 31 December 2019 was 25.5 million people at the back of an annual increase of 349,800 people.
There is no one left untouched by the charm of the multibillion-dollar global boom in cannabis. Its glorious journey from a criminalized drug to being used in over 20 countries for treating medical conditions.
No wonder the cannabis stocks are on the edge of a green rush. Don’t miss out on the happenings in the cannabis sector and take advantage of the growth phase of this sector by subscribing to our report on Marijuana stocks in Australia.
Find out the drivers for the rise in cannabis stock rates Even though the cannabis sector is in its growing phase, Australian cannabis stocks have already started to rise actively due to a hastily increasing patient base, and a legislative landscape that is gradually beginning to liberalise.
Outreach and future of cannabis stocks As countries liberalise regulation for medical and recreational use of cannabis, it is predicted that the industry would grow sharply in upcoming years The global cannabis market stands currently at around $8 billion and it is expected that the hemp derived CBD market to hit approximately $22 billion by 2022.
Key Players in the sector Althea Group Holdings Limited (ASX: AGH) and Cann Group Limited (ASX: CAN) are amongst the top players. Other Australia cannabis market players are- MGC Pharmaceuticals Ltd (ASX: MXC), Elixinol Global Limited (ASX: EXL), THC Global Group Limited (ASX: THC), AusCann Group Holdings Limited (ASX: AC8)